




























参考图片
Expression of IFN- by stimulated CD4+ and CD4-BALB/c spleen cells. Splenocytes from BALB/C mice were stimulated for 4 hrs with PMA (5 ng/ml, Sigma, Cat. No. P-8139) and Ionomycin (500 µg/ml, Sigma Cat. No. I-0634) in the presence of Brefeldin A (GolgiPlug, Cat. No. 555029). Cells were harvested, fixed, permeabilized and stained with APC rat anti-mouse CD4 (APC-RM4-5, Cat. No. 553051) and either rat anti-mouse IFN-γ antibody (PE-Cy7-XMG1.2, Cat. No. 557649), (left panel) or immunoglobulin isotype control (PE-Cy7-R3-34, Cat. No. 557645), (right panel) by using the BD Pharmingen staining protocol. To demonstrate specificity of staining the binding of PE-Cy7-XMG1.2 was blocked by preincubation of the fixed/permeabilized cells with an excess of unlabelled XMG1.2 antibody (5 µg, Cat. No. 554409, data not shown) prior to stainining. The quadarant markers for the bivariate dot plots were set based on the autofluorescence and isotype controls.
Expression of IFN- by stimulated CD4+ and CD4-BALB/c spleen cells. Splenocytes from BALB/C mice were stimulated for 4 hrs with PMA (5 ng/ml, Sigma, Cat. No. P-8139) and Ionomycin (500 µg/ml, Sigma Cat. No. I-0634) in the presence of Brefeldin A (GolgiPlug, Cat. No. 555029). Cells were harvested, fixed, permeabilized and stained with APC rat anti-mouse CD4 (APC-RM4-5, Cat. No. 553051) and either rat anti-mouse IFN-γ antibody (PE-Cy7-XMG1.2, Cat. No. 557649), (left panel) or immunoglobulin isotype control (PE-Cy7-R3-34, Cat. No. 557645), (right panel) by using the BD Pharmingen staining protocol. To demonstrate specificity of staining the binding of PE-Cy7-XMG1.2 was blocked by preincubation of the fixed/permeabilized cells with an excess of unlabelled XMG1.2 antibody (5 µg, Cat. No. 554409, data not shown) prior to stainining. The quadarant markers for the bivariate dot plots were set based on the autofluorescence and isotype controls.